DexCom (NASDAQ:DXCM) Downgraded to “Hold” at StockNews.com

DexCom (NASDAQ:DXCM) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Thursday.

A number of other brokerages also recently commented on DXCM. Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. Canaccord Genuity Group raised their target price on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Citigroup boosted their price target on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. UBS Group raised their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, Raymond James boosted their target price on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $141.67.

DexCom Stock Down 2.1 %

DexCom stock opened at $127.42 on Thursday. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $50.67 billion, a PE ratio of 82.21, a PEG ratio of 2.19 and a beta of 1.23. The firm’s fifty day moving average is $132.94 and its 200 day moving average is $121.16. DexCom has a 12-month low of $74.75 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. As a group, sell-side analysts predict that DexCom will post 1.78 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the transaction, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Jon Brown sold 629 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the transaction, the executive vice president now owns 68,212 shares of the company’s stock, valued at $8,611,765. The disclosure for this sale can be found here. Insiders have sold 190,004 shares of company stock valued at $25,610,270 in the last 90 days. 0.41% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On DexCom

A number of institutional investors and hedge funds have recently made changes to their positions in DXCM. Team Hewins LLC increased its stake in DexCom by 3.4% in the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after acquiring an additional 83 shares during the last quarter. Bleakley Financial Group LLC increased its position in shares of DexCom by 1.3% in the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after purchasing an additional 87 shares during the last quarter. Stableford Capital II LLC raised its stake in DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after purchasing an additional 88 shares in the last quarter. D Orazio & Associates Inc. lifted its position in DexCom by 0.8% during the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after purchasing an additional 93 shares during the last quarter. Finally, Gulf International Bank UK Ltd grew its stake in DexCom by 0.3% in the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after buying an additional 93 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.